CAMP CAMP4 THERAPEUTICS CORP revenue, earnings and financials
For the quarter ended June 30, 2026, CAMP4 THERAPEUTICS CORP reported revenue of $1.78M (up 18.8% from a year earlier), net income of −$33.5M and diluted EPS of −$0.58; over the last four quarters revenue was $4.22M and net income −$107M; for the fiscal year ended December 2025 revenue was $3.50M, up 436.5% on the year before.
CAMP annual revenue and earnings
- Fiscal year ended Dec 2025: revenue $3.50M, gross profit n/a, operating income −$52.6M, net income −$80.4M (margin -2298.5%), EPS −$2.65
- Fiscal year ended Dec 2024: revenue $652K, gross profit n/a, operating income −$53.1M, net income −$51.8M (margin -7943.4%), EPS −$11.04
- Fiscal year ended Dec 2023: revenue $350K, gross profit n/a, operating income −$51.9M, net income −$49.3M (margin -14083.1%), EPS −$124.80
CAMP quarterly revenue and earnings
- Quarter ended Jun 30, 2026: revenue $1.78M (up 18.8% year over year), net income −$33.5M, EPS −$0.58
- Quarter ended Mar 31, 2026: revenue $1.29M (up 50.8% year over year), net income −$18.3M, EPS −$0.32
- Quarter ended Dec 31, 2025 (from the annual report): revenue $348K (down 46.6% year over year), net income −$40.3M, EPS −$0.86
- Quarter ended Sep 30, 2025: revenue $795K, net income −$15.1M, EPS −$0.55
- Quarter ended Jun 30, 2025: revenue $1.50M, net income −$12.6M, EPS −$0.62
- Quarter ended Mar 31, 2025: revenue $858K, net income −$12.4M, EPS −$0.62
- Quarter ended Dec 31, 2024 (from the annual report): revenue $652K, net income −$13.3M, EPS $65.72
- Quarter ended Sep 30, 2024: revenue $0 (down 100.0% year over year), net income −$13.5M, EPS −$24.19
- Quarter ended Jun 30, 2024: revenue $0, net income −$12.6M, EPS −$26.00
- Quarter ended Mar 31, 2024: revenue $0, net income −$12.5M, EPS −$26.57
- Quarter ended Dec 31, 2023 (from the annual report): revenue n/a, net income −$13.0M, EPS n/a
- Quarter ended Sep 30, 2023: revenue $350K, net income −$11.7M, EPS −$29.21
- Quarter ended Jun 30, 2023: revenue n/a, net income −$12.1M, EPS n/a
- Quarter ended Mar 31, 2023: revenue n/a, net income −$12.5M, EPS n/a
CAMP cash flow, buybacks and dividends
- Fiscal year ended Dec 2025: operating cash flow −$29.6M, share buybacks n/a, dividends $0.00 per share
- Fiscal year ended Dec 2024: operating cash flow −$45.6M, share buybacks n/a, dividends $0.00 per share
- Fiscal year ended Dec 2023: operating cash flow −$44.2M, share buybacks n/a
CAMP balance sheet
- Jun 30, 2026: cash $86.4M, total assets $93.4M, total liabilities $94.1M, shareholders' equity −$693K
- Mar 31, 2026: cash $99.2M, total assets $105M, total liabilities $74.6M, shareholders' equity $30.9M
- Dec 31, 2025: cash $110M, total assets $118M, total liabilities $70.1M, shareholders' equity $47.7M
- Sep 30, 2025: cash $75.3M, total assets $86.4M, total liabilities $27.7M, shareholders' equity $58.7M
- Jun 30, 2025: cash $39.1M, total assets $51.3M, total liabilities $11.3M, shareholders' equity $40.0M
- Mar 31, 2025: cash $49.3M, total assets $62.8M, total liabilities $11.2M, shareholders' equity $51.6M
- Dec 31, 2024: cash $64.0M, total assets $78.3M, total liabilities $15.2M, shareholders' equity $63.1M
- Sep 30, 2024: cash $2.53M, total assets $21.4M, total liabilities $18.2M, shareholders' equity −$159M
What is CAMP's revenue?
CAMP4 THERAPEUTICS CORP reported $4.22M of revenue over its last four quarters, through June 30, 2026.
Is CAMP profitable?
No. CAMP4 THERAPEUTICS CORP lost $107M over the last four quarters.
What is CAMP's EPS?
Diluted earnings per share over the last four quarters were −$2.31; −$0.58 in the latest quarter.